Takumi Ito

Profile Information

J-GLOBAL ID: 201101097064605496
researchmap Member ID: 6000028333

サリドマイドおよびその標的因子セレブロンの研究を行っています。
最近ではセレブロンを標的とする新しい薬剤の研究開発にも携わっています。

Research History

Apr, 2022 - Present

Tokyo Medical University
Apr, 2016 - Mar, 2022

Tokyo Medical University
Oct, 2013 - Mar, 2016

Tokyo Medical University
Apr, 2012 - Sep, 2013

Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology
Oct, 2008 - Mar, 2012

Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology

Education

Apr, 2004 - Sep, 2008

Department of Biological Information, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology
Apr, 2000 - Mar, 2004

Department of Biosciences, School of Bioscience and Biotechnology, Tokyo Institute of Technology

Papers

Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drugs-induced thromboembolism.

Kiwamu Hatakeyama, Yoshikane Kikushige, Daisuke Ishihara, Shunsuke Yamamoto, Gentaro Kawano, Taro Tochigi, Toshihiro Miyamoto, Teppei Sakoda, Andy Christoforou, Yuya Kunisaki …

Blood advances, Jan 1, 2024
Protein degraders -from thalidomide to new PROTACs

Takumi Ito

The Journal of Biochemistry, Dec 23, 2023 Lead authorLast authorCorresponding author
ZNF276 and WIZ are CRBN neosubstrates involved in the anti-angiogenic activity of thalidomide and immunomodulatory drugs

Takumi Ito, Tomoko Asatsuma-Okumura, Akinori Endo, Junichi Yamamoto, Yoshiko Iwai, Yuki Yamaguchi, Mikihiko Naito, Hiroshi Handa, Yasushi Saeki

Nov 20, 2023 Last authorCorresponding author
Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4.

Akihiro Kimura, Takeshi Takagi, Thiprampai Thamamongood, Satoshi Sakamoto, Takumi Ito, Iwao Seki, Masahiro Okamoto, Hiroyuki Aono, Satoshi Serada, Tetsuji Naka …

Annals of the rheumatic diseases, Jul 2, 2023 Peer-reviewed
Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa

Chemical Society Reviews, 51(15) 6234-6250, Aug 1, 2022 Peer-reviewedInvited
PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates.

Nobuyuki Shimizu, Tomoko Asatsuma-Okumura, Junichi Yamamoto, Yuki Yamaguchi, Hiroshi Handa, Takumi Ito

Communications biology, 4(1) 1277-1277, Nov 11, 2021 Last authorCorresponding author
Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.

Takumi Ito, Yuki Yamaguchi, Hiroshi Handa

Cell chemical biology, May 3, 2021 Peer-reviewedInvitedLead author
Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.

Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Mika Sunakawa-Kii, Koiti Inokuchi, Rimpei Morita, Hideto Tamura

Molecular cancer therapeutics, Apr 20, 2021
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.

Mitsuhito Hirano, Yoichi Imai, Yuta Kaito, Takahiko Murayama, Kota Sato, Tadao Ishida, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri …

Journal of experimental & clinical cancer research : CR, 40(1) 110-110, Mar 23, 2021
Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.

Tomomi Sato, Takumi Ito, Hiroshi Handa

Frontiers in cell and developmental biology, 9 629326-629326, 2021
ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells.

Junichi Yamamoto, Tetsufumi Suwa, Yuki Murase, Shumpei Tateno, Hirotaka Mizutome, Tomoko Asatsuma-Okumura, Nobuyuki Shimizu, Tsutomu Kishi, Shuji Momose, Masahiro Kizaki …

Nature chemical biology, 16(11) 1208-1217, Nov, 2020
Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia.

Taro Tochigi, Toshihiro Miyamoto, Kiwamu Hatakeyama, Teppei Sakoda, Daisuke Ishihara, Hidetoshi Irifune, Takahiro Shima, Koji Kato, Takahiro Maeda, Takumi Ito …

Blood, 135(24) 2146-2158, Jun 11, 2020
Molecular Mechanisms of the Teratogenic Effects of Thalidomide.

Tomoko Asatsuma-Okumura, Takumi Ito, Hiroshi Handa

Pharmaceuticals (Basel, Switzerland), 13(5), May 13, 2020 Peer-reviewedInvitedCorresponding author
Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide.

Shumpei Tateno, Midori Iida, Satoshi Fujii, Tetsufumi Suwa, Miki Katayama, Haruka Tokuyama, Junichi Yamamoto, Takumi Ito, Satoshi Sakamoto, Hiroshi Handa …

Scientific reports, 10(1) 4012-4012, Mar 4, 2020 Peer-reviewed
サリドマイド催奇性の解明

朝妻知子, 伊藤拓水, 山本淳一, 清水誠之, 佐藤智美, 浅川和秀, 半田宏

東京医科大学雑誌, 78(1) 86-86, Jan, 2020
Molecular mechanisms of thalidomide and its derivatives.

Takumi Ito, Hiroshi Handa

Proceedings of the Japan Academy. Series B, Physical and biological sciences, 96(6) 189-203, 2020
p63 is a cereblon substrate involved in thalidomide teratogenicity.

Tomoko Asatsuma-Okumura, Hideki Ando, Marco De Simone, Junichi Yamamoto, Tomomi Sato, Nobuyuki Shimizu, Kazuhide Asakawa, Yuki Yamaguchi, Takumi Ito, Luisa Guerrini …

Nature chemical biology, 15(11) 1077-1084, Nov, 2019 Peer-reviewed
Molecular mechanisms of cereblon-based drugs.

Asatsuma-Okumura T, Ito T, Handa H

Pharmacology & therapeutics, 202 132-139, Jun, 2019 Peer-reviewed
Cereblon Control of Zebrafish Brain Size by Regulation of Neural Stem Cell Proliferation.

Hideki Ando, Tomomi Sato, Takumi Ito, Junichi Yamamoto, Satoshi Sakamoto, Nobuhiro Nitta, Tomoko Asatsuma-Okumura, Nobuyuki Shimizu, Ryota Mizushima, Ichio Aoki …

iScience, 15 95-108, May 31, 2019 Peer-reviewed
免疫調節薬は骨髄腫細胞のPD-L1発現誘導によりT細胞抑制するが、durvalumabとの併用で解除できる(Immunomodulatory drug-induced T-cell suppression via PD-L1 upregulation on myeloma cells is recovered by durvalumab)

石橋真理子, 山本淳一, 伊藤拓水, 半田宏, 猪口孝一, 田村秀人

International Journal of Myeloma, 9(1) 76-76, May, 2019

Misc.

Development of new cereblon modulators and their target proteins.

朝妻知子, 半田宏, 伊藤拓水

月刊血液内科, 84(4), 2022
Targeted Protein Degradation: Molecular Glue Degrader

伊藤拓水, 朝妻知子, 半田宏

月刊細胞, 53(3), 2021
Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Mitsuhito Hirano, Yoichi Imai, Takahiko Murayama, Kota Sato, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri, Hiroshi Yasui, Noriko Gotoh …

BLOOD, 134, Nov, 2019
プロテアソームと疾病研究の動向セレブロンモジュレーターによるタンパク質分解誘導創薬

清水誠之, 伊藤拓水, 半田宏

月刊メディカル・サイエンス・ダイジェスト, 45(4), 2019
Upregulation of PD-L1 on Myeloma Cells By Immunomodulatory Agents Potentiates the Effect of Durvalumab

Mariko Ishibashi, Junichi Yamamoto, Takumi Ito, Hiroshi Handa, Koiti Inokuchi, Hidemi Takahashi, Hideto Tamura

BLOOD, 132, Nov, 2018
The function of the CRBN E3ubiquitin ligase : A primary direct target of thalidomide

256(8) 891-895, Feb 20, 2016
免疫調節薬（IMiDs）標的因子セレブロンの機能解析

伊藤拓水, 朝妻知子, GUPTA VIPUL, 真鍋正彦, 山本淳一, 安藤秀樹, 半田宏

東京医科大学雑誌 = The Journal of Tokyo Medical University, 73(4) 429-429, Oct 30, 2015
Effects of thalidomide/IMiDs mediated by Cereblon E3 ubiquitin ligase

243(6) 503-507, Nov 10, 2012
Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding (vol 26, pg 1338, 2012)

A. Lopez-Girona, D. Mendy, T. Ito, K. Miller, A. K. Gandhi, J. Kang, S. Karasawa, G. Carmel, P. Jackson, M. Abbasian …

LEUKEMIA, 26(11) 2445-2446, Nov, 2012
Recent advances in searching for molecular targets of IMiDs

64(4) 440-445, Apr, 2012
Mechanisms of Thalidomide Teratogenicity

ITO Takumi, ANDO Hideki, HANDA Hiroshi

KAGAKU TO SEIBUTSU, 49(12) 819-824, Dec 1, 2011
Teratogenic effects of thalidomide: molecular mechanisms

Takumi Ito, Hideki Ando, Hiroshi Handa

CELLULAR AND MOLECULAR LIFE SCIENCES, 68(9) 1569-1579, May, 2011
Molecular basis of thalidomide teratogenicity : the biological activity of cereblon

62(1) 71-75, Jan, 2011
S16-4 サリドマイドによる催奇性の分子機構 : ナノビーズ技術を用いたアプローチ(シンポジウムS16 薬物有害反応の発現機構と予測の新展開,臨床から学び臨床へと還元する医療薬学)

伊藤拓水, 安藤秀樹, 山口雄輝, 半田宏

日本医療薬学会年会講演要旨集, 20 236-236, Oct 25, 2010
ついに解明! サリドマイドが起こす催奇性の謎--標的分子セレブロンを突き止めたFGビーズ

伊藤拓水, 坂本聡, 半田宏

化学, 65(8) 47-51, Aug, 2010
サリドマイド催奇性の原因因子の発見

伊藤拓水, 安藤秀樹, 鈴木孝幸, 小椋利彦, 山口雄輝, 半田宏

実験医学, 28 2115-2118, 2010

Research Projects

Controlling the lifetime of proteins using chemical degraders

Grants-in-Aid for Scientific Research, Grant-in-Aid for Transformative Research Areas (A), Japan Society for the Promotion of Science, Apr, 2023 - Mar, 2028
Elucidation of the therapeutic mechanisms of IMiDs

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science, Apr, 2021 - Mar, 2024
Chemical protein knockdown technology and cell regulation

Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area), Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area), Japan Society for the Promotion of Science, Jun, 2018 - Mar, 2023
Elucidation of the molecular basis of IMiDs' action

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science, Apr, 2017 - Mar, 2020

Ito Takumi

Profile Information

Research History

Education

Papers

Misc.

Research Projects

Menu

Coauthors